Showing 7701-7710 of 9914 results for "".
- Vyne Therapeutics Doses First Patient in Phase 2b Vitiligo Trial of Novel BET Inhibitorhttps://practicaldermatology.com/news/vyne-therapeutics-doses-first-patient-phase-2b-vitiligo-trial-novel-bet-inhibitor/2467132/Vyne Therapeutics announced that the first subject has been dosed in a phase 2b trial evaluating VYN201 in subjects with either active or stable nonsegmental vitiligo. VYN201 is a novel pan-bromodomain and extra-terminal domain (BET) inhibitor designed for local administration. Topline data from
- FDA Approves Gel for Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-gel-axillary-hyperhidrosis/2467109/The US Food and Drug Administration (FDA) has approved a new prescription gel used to treat axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 and older, manufacturer Botanix Pharmaceuticals announced. Sofdra (sofpironium) is the first chemical entity approved b
- PD-1 Gene Variants Linked to Melanoma Riskhttps://practicaldermatology.com/news/pd-1-gene-variants-linked-melanoma-risk/2467088/A recent study has highlighted significant associations between specific single nucleotide variants (SNVs) in the PD-1 and PD-L1 genes and the risk of metastatic melanoma (MM). Researchers conducted the study at IRCCS Ospedale Policlinico San Martino in Genova, Italy, and included 125 patients wi
- DermTech Files for Voluntary Chapter 11 Protectionhttps://practicaldermatology.com/news/dermtech-files-voluntary-chapter-11-protection/2467087/DermTech announced it has filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the company’s strategic alternatives review process. DermTech, which is a provider of noninvasive skin genomics technol
- Recurrence in Patients with Thin Melanomas Linked with Poor Prognosis, Despite Rarityhttps://practicaldermatology.com/news/recurrence-patients-thin-melanomas-linked-poor-prognosis-despite-rarity/2467070/While rare, the recurrence of melanomas in patients with thin melanomas was linked with poorer prognosis and lower survival rates, a single-center analysis reported. "The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm)," the researchers wrote in their study, publi
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://practicaldermatology.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- Adtralza Pre-Filled Pen Now Available for Canadian Atopic Dermatitis Patientshttps://practicaldermatology.com/news/adtralza-pre-filled-pen-now-available-canadian-atopic-dermatitis-patients/2467019/A new Adtralza® (tralokinumab injection) pre-filled pen has been made available for the first time in Canada for the treatment of moderate-to-severe atopic dermatitis (AD), according to a press announcement from LEO Pharma Inc. The single-use 2 mL pre-filled pen "simplifies the
- More Positive Upadacitinib Data Presentedhttps://practicaldermatology.com/news/more-positive-upadacitinib-data-presented/2467018/New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from June 8-10 in Chicago, Illinois, built on previously published top-line results comparing upadacitinib to dupilumab by demonstrating superiority for all ranked secondary endpoints at varying response levels and time
- FDA Gives Green Light to InnoCare's Clinical Trial of TYK2 Inhibitor ICP-332 for ADhttps://practicaldermatology.com/news/fda-gives-green-light-innocares-clinical-trial-tyk2-inhibitor-icp-332-ad/2467004/InnoCare Pharma announced that the FDA has cleared its investigational new drug (IND) application for its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332. ICP-332 is a potent and selective TYK2 inhibitor. It achieved multiple efficacy endpoints in the China phase 2 study for the treatmen
- Parental E-Cigarette Use Linked to Pediatric ADhttps://practicaldermatology.com/news/parental-e-cigarette-use-linked-pediatric-ad/2467003/Electronic cigarette use by parents is associated with increased chances of pediatric atopic dermatitis, according to an article published last month by JAMA Dermatology. In a retrospective cross-sectional analysis of the 2014 to 2018 National Health Interview Survey, researchers found tha